The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Atazanavir Mylan

150 milligram(s) Capsule, hard

Mylan S.A.S.EU/1/16/1091/001-003

Main Information

Trade NameAtazanavir Mylan
Active SubstancesAtazanavir sulfate
Strength150 milligram(s)
Dosage FormCapsule, hard
Licence HolderMylan S.A.S.
Licence NumberEU/1/16/1091/001-003

Group Information

ATC CodeJ05AE Protease inhibitors
J05AE08 atazanavir


Licence Issued22/08/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back